Oppenheimer Maintains Outperform on Edwards Lifesciences, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia has reiterated an 'Outperform' rating for Edwards Lifesciences, maintaining a price target of $90.
September 12, 2024 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has reiterated its 'Outperform' rating for Edwards Lifesciences, maintaining a price target of $90, indicating confidence in the company's performance.
The reaffirmation of an 'Outperform' rating and a maintained price target of $90 by Oppenheimer suggests a positive outlook for Edwards Lifesciences. This can lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100